Table 2.
History of prior ulcerative colitis therapies at enrollment for patients with ulcerative colitis.
| Ulcerative colitis therapy groups (at beginning of enrollment visit) | ||||
|---|---|---|---|---|
| Total | 5-ASAsa | BIO/JAKia | Difference (95% CI)b | |
| Prior UC therapiesc | ||||
| Biologic experienced | n = 605 | n = 290 | n = 315 | |
| n (%) | 323 (53.39%) | 8 (2.76%) | 315 (100.00%) | −97.2 (−99.1, −95.4) |
| Number of prior biologicsd, n (%) | n = 605 | n = 290 | n = 315 | |
| 0 | 491 (81.2%) | 282 (97.2%) | 209 (66.3%) | 30.9 (25.3, 36.4) |
| 1 | 75 (12.4%) | 7 (2.4%) | 68 (21.6%) | −19.1 (−24.1, −14.3) |
| 2+ | 39 (6.4%) | 1 (0.3%) | 38 (12.1%) | −11.7 (−15.4, −8.1) |
| 5-ASAs experienced | n = 605 | n = 290 | n = 315 | |
| n (%) | 517 (85.5%) | 290 (100.0%) | 227 (72.1%) | 27.9 (23.0, 32.9) |
| ISTs experienced | n = 605 | n = 290 | n = 315 | |
| n (%) | 121 (20.0%) | 11 (3.8%) | 110 (34.9%) | −31.1 (−36.8, −25.4) |
| Corticosteroid experienced | n = 605 | n = 290 | n = 315 | |
| n (%) | 352 (58.2%) | 129 (44.5%) | 223 (70.8%) | −26.3 (−33.9, −18.7) |
| Antibiotic experienced | n = 605 | n = 290 | n = 315 | |
| n (%) | 117 (19.3%) | 44 (15.2%) | 73 (23.2%) | −8.0 (−14.2, −1.8) |
| Duration of current UC therapy (years) | n = 604 | n = 289 | n = 315 | |
| Mean (SD) | 2.5 (3.7) | 3.5 (4.5) | 1.6 (2.3) | 1.9 (1.3, 2.5) |
Abbreviations: 5-ASAs, 5-aminosalicylic acids; IST, immunosuppressant therapies; JAKi, Janus kinase inhibitors; 5-ASAs alone (5-ASAs); biologics/JAKi alone or in combination with ISTs or 5-ASAs (BIO/JAKi).
Concomitant (eg, currently taking) use of steroids or antibiotics at the time of enrollment is allowed in the UC therapy groups.
Unadjusted mean difference (95% CI) between groups for continuous variables and difference in percentage points (95% CI) between groups for categorical variables.
UC therapies included: 5-ASAs (mesalamine, balsalazide, sulfasalazine), ISTs (methotrexate, 6 mercaptopurine, azathioprine, tacrolimus, cyclosporine, other ISTs), or biologics/JAKi (tumor necrosis factor inhibitors [TNFi]: adalimumab and its biosimilar, certolizumab, golimumab, infliximab, and its biosimilar; interleukin-12/23 inhibitor [IL-12/23i]: ustekinumab; integrin α4β7 inhibitor: natalizumab; integrin α4 inhibitor: vedolizumab; JAKi: tofacitinib).
Prior to current treatment.